其他臨床專科系

精準醫學科的依據指引

12 個學習主題共依據 17 份臨床指引與文獻。點主題名稱看它的學習重點。

腫瘤基因體檢測與標靶治療1 份

  1. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion|ASCO|2022

液態切片與循環腫瘤DNA1 份

  1. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group|ESMO PMWG|2022
    ESMO的全部指引 · Pascual J, Attard G, Bidard FC, et al. · DOI · CC BY-NC-ND 4.0

藥物基因體學與劑量個人化1 份

  1. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines|DPWG|2020
    Lunenburg CATC, van der Wouden CH, Nijenhuis M, et al. · DOI · CC BY 4.0

生物標記與伴隨式診斷2 份

  1. Biomarker and Companion Diagnostics—A Review of Medicinal Products Approved by the European Medicines Agency|Frontiers in Medicine|2021
    Orellana García LP, Ehmann F, Hines PA, et al. · DOI · CC BY 4.0
  2. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update|International Journal of Cancer|2013
    Duffy MJ, Lamerz R, Haglund C, et al. · DOI · CC BY-NC-ND 3.0

免疫治療生物標記判讀2 份

  1. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach|Annals of Oncology|2019
    Luchini C, Bibeau F, Ligtenberg MJL, et al. · DOI
  2. Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee|Journal for ImmunoTherapy of Cancer|2024
    Monette A, Warren S, Barrett JC, et al. · DOI · CC BY-NC 4.0

次世代定序基因套組判讀1 份

  1. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group|ESMO PMWG|2024
    ESMO的全部指引 · Mosele MF, Westphalen CB, Stenzinger A, et al. · DOI · CC BY-NC-ND 4.0

分子腫瘤委員會2 份

  1. Molecular Tumor Boards: current practice and future needs|Annals of Oncology|2017
    van der Velden DL, van Herpen CML, van Laarhoven HWM, et al. · DOI
  2. Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations|The Oncologist|2021

體細胞與生殖細胞突變區辨1 份

  1. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group|ESMO PMWG|2019
    ESMO的全部指引 · Mandelker D, Donoghue M, Talukdar S, et al. · DOI · CC BY-NC 4.0

多基因風險評分1 份

  1. Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps|ICDA PRS Task Force|2021
    Polygenic Risk Score Task Force of the International Common Disease Alliance, Adeyemo A, Balaconis MK, et al. · DOI · CC BY-NC-ND

精準用藥基因指引1 份

  1. The CPIC Guideline for SLCO1B1, ABCG2, and CYP2C9 Genotypes and Statin-Associated Musculoskeletal Symptoms|CPIC|2022
    Cooper‐DeHoff RM, Niemi M, Ramsey LB, et al. · DOI

數據整合與生物資訊分析2 份

  1. AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions|Clinical and Experimental Medicine|2025
    Hsu CY, Askar S, Alshkarchy SS, et al. · DOI · CC BY-NC-ND 4.0
  2. GA4GH: International policies and standards for data sharing across genomic research and healthcare|GA4GH|2021
    Rehm HL, Page AJH, Smith L, et al. · DOI · CC BY-NC-ND 4.0

精準預防與早期偵測2 份

  1. Multi-cancer early detection tests: Attributes for clinical implementation|Cancer Biomarkers|2025
    Ebbert JO, Hawk ET, Chambers CV, et al. · DOI · CC BY-NC 4.0
  2. Personalized early detection and prevention of breast cancer: ENVISION consensus statement|ENVISION 國際共識|2020
    Pashayan N, Antoniou AC, Ivanus U, et al. · DOI · CC BY 4.0

使用 Google 帳號登入,第一次登入時選擇科別即可開始;已經在用?直接登入